Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) finished Friday with an addition of $0.01 to close at $1.73, an upside of 0.58 percent. An average of 1,991,300 shares of common stock have been traded in the last five days. There was a fall of -$0.1400 in the past week, and it reached a new high 4 times over the past 12 months. The last 20 days have seen an average of 1,734,335 shares traded, while the 50-day average volume stands at 2,598,190.
LXRX stock has decreased by -24.78% in the last month. The company shares reached their 1-month lowest point of $1.6800 on 08/07/23. With the stock rallying to its 52-week high on 05/05/23, shares of the company touched a low of $1.68 and a high of $3.79 in 52 weeks. It has reached a new high 14 times so far this year and lost -9.42% or -$0.1800 in price. In spite of this, the price is down -54.34% from the 52-week high.
Valuation Metrics
Lexicon Pharmaceuticals Inc. (LXRX) stock’s beta is 1.18. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 4349.05, the price-to-book (PB) ratio at 3.68.
Financial Health
The quick ratio of Lexicon Pharmaceuticals Inc. for the three months ended June 29 was 5.40, and the current ratio was 5.40, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.55 and a total debt to equity ratio of 0.00 for the quarter ending June 29. Its gross profit as reported stood at $0.14 million compared to revenue of $0.14 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Lexicon Pharmaceuticals Inc.’s return on assets was -61.70%.
Earnings Surprise
For the three-month period that ended June 29, Lexicon Pharmaceuticals Inc. had $154.47 million in cash and short-term investments compared to $98.77 million in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$44.9 million in the quarter, while revenues of -$31.93 million were grew 45.23%. The analyst consensus anticipated Lexicon Pharmaceuticals Inc.’s latest quarter earnings to come in at -$0.17 per share, but it turned out to be -$0.22, a -29.40% surprise. For the quarter, EBITDA amounted to -$43.82 million. Shareholders own equity worth $0.24 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Lexicon Pharmaceuticals Inc. (LXRX) price momentum. RSI 9-day as of the close on 11 August was 31.72%, suggesting the stock is Neutral, with historical volatility in this time frame at 67.13%.
As of today, LXRX’s price is $1.7400 -7.49% or -$0.1400 from its 5-day moving average. LXRX is currently trading -21.72% lower than its 20-day SMA and -23.45% lower than its 100-day SMA. However, the stock’s current price level is -47.58% below the SMA50 and -10.82% below the SMA200.
The stochastic %K and %D were 11.80% and 14.12%, respectively, and the average true range (ATR) was 0.1164. With the 14-day stochastic at 14.29% and the average true range at 0.1218, the RSI (14) stands at 33.20%. The stock has reached -0.0867 on the 9-day MACD Oscillator while the 14-day reading was at -0.1398.
Analyst Ratings
Jefferies launched coverage on Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) in its analyst report released on March 07, 2023. The firm assigned the stock a Hold rating. The consensus rating for Lexicon Pharmaceuticals Inc. (LXRX) among analysts is Overweight. According to current brokerage recommendations, 0 brokerage firms advise that investors sell LXRX, while 2 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 2 others rate it as a “buy”.
